Skip to content
Open access

Combination of live-attenuated and adenovirus-based vaccines provides immediate and durable protection against Yersinia pestis in mice

Sep 2026 · Molecular Therapy: Nucleic Acids · Vol 37 · 0 citations · 55 references
Medicine

TL;DR

Mice immunized with both strategies were completely protected and elicited robust and durable humoral and cellular immune responses through 6 months, and these vaccines and strategies are suitable for reactive (emergency) and preventive (in endemic regions) use.

Abstract

Yersinia pestis is the etiological agent of pandemic-causing plague with no Food and Drug Administration (FDA)-approved vaccines. The natural emergence or intentional release of antimicrobial-resistant strains are alarming, necessitating development of new-generation vaccines and immunization strategies that produce rapid and durable immunity. Herein, we evaluated immediate (within 7 days) or long-term (6 months) protection and immune responses by combining patented live-attenuated vaccines (LAVs) with a trivalent adenovirus-type 5-based vaccine (Ad5-YFV) in C57BL/6 mice. Animals were immunized with either a two-dose prime-pull strategy (intramuscular [i.m.] injection of LAVs followed by intranasal [i.n.] instillation of Ad5-YFV, 21 days apart) or a 1-dose strategy by simultaneous administration of LAVs (i.m.) and Ad5-YFV (i.n.). Animals immunized with both strategies were either challenged after 6 months or, with the simultaneous strategy, 7 days post-vaccination in lethal pneumonic or bubonic Y. pestis CO92 infection models. Mice immunized with both strategies were completely protected and elicited robust and durable humoral and cellular immune responses through 6 months. Simultaneous vaccination also protected animals against bubonic (100%) and pneumonic (80%) challenges 7 days post-vaccination with rapid induction of immunoglobulin M (IgM), IgG3, and total IgG humoral responses. Thus, these vaccines and strategies are suitable for reactive (emergency) and preventive (in endemic regions) use.

Read PDF

Similar papers

Open access Nov 2026

Protection against lethal pneumonic plague by intramuscular F1V vaccine incorporating a colloidal TLR4-TLR7 dual adjuvant

Yersinia pestis is a facultative intracellular bacterium that causes plague, which manifests in bubonic form and the more severe pneumonic and septicemic forms. There is no FDA-approved vaccine for plague, and those used in the past for human prophylaxis were suboptimal against aerosol infection or nonencapsulated s...

Michael L. Davies, Jennifer L. Dankmeyer, Nathaniel O. Rill et al. · 0 citations
Open access Oct 2026

An adenovirus-based mucosal vaccine induces cross-neutralizing antibodies and protects against lethal H5N1 infection in ferrets

Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.

Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al. · 0 citations
Review Open access Oct 2026

Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development

Dengue is one of the most rapidly spreading arboviral diseases worldwide, and the development of effective vaccines has long been constrained by antibody-dependent enhancement (ADE) and the difficulty of inducing protective immunity against multiple viral serotypes. Although several live-attenuated dengue vaccines have...

Xuebaihe Ma, Meng-Yuan Zhao, Ya-Qun Xu et al. · 0 citations
Open access Oct 2026

Comparative Preclinical Evaluation of Three Recombinant Brucella Vaccine Formulations, BruVac-Pro, BruVac-CPX and BruVac-FLU, in a Murine Brucella melitensis Challenge Model

Background/Objectives: Brucellosis remains a widespread zoonosis, yet no licensed human vaccine exists and the live attenuated vaccines used in animals are unsuitable for people because of residual virulence and the risk of accidental infection. Recombinant platforms are attractive alternatives, but direct head-to-head...

B. Yespembetov, S. Alpysbayeva, M. Sarmykova et al. · 0 citations
Open access Oct 2026

Synthetic Particulate Subunit Vaccines Co‐Delivering Multiple Antigens Induce Protective Immunity Against Melioidosis

Melioidosis, caused by Burkholderia pseudomallei , is a life‐threatening disease and a potential biological warfare agent. Currently, no licensed vaccine is available for prevention. To address this unmet need, we bioengineered an endotoxin‐free Escherichia coli strain to assemble biopolymer inclusions coated wit...

M. Kabir, Shu-Xiong Chen, Justine B. Bendo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.